Skip to Content

DDAVP (desmopressin) Disease Interactions

There are 4 disease interactions with DDAVP (desmopressin):

Major

Desmopressin (applies to DDAVP) renal dysfunction

Major Potential Hazard, High plausibility.

The use of desmopressin is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50 mL/min).

References

  1. Affarah HB, Mars RL, Someren A, Smith HW 3d, Heymsfield SB "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion." South Med J 77 (1984): 918-21
  2. "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals, St. Louis, MO.
  3. "Product Information. DDAVP (desmopressin)." Rhone-Poulenc Rorer, Collegeville, PA.
  4. "Product Information. Pitressin (vasopressin)." Parke-Davis, Morris Plains, NJ.
View all 4 references
Major

Vasopressin/desmopressin (applies to DDAVP) fluid overload/hyponatremia

Major Potential Hazard, High plausibility. Applicable conditions: Fluid Retention, Seizures, Congestive Heart Failure, Migraine, Asthma

Water intoxication and hyponatremia may occur during therapy with vasopressin or desmopressin due to their antidiuretic action. Patients are most likely to experience this problem if their fluid intake is excessive or if they do not require antidiuresis, such as when they are administered these agents for their hemostatic effects. Fluid intake should be adjusted carefully to avoid overhydration, particularly in children, elderly, and patients with conditions that may be exacerbated by fluid retention, including epilepsy, migraine, asthma, and heart failure. Patients should be monitored for signs of water intoxication (e.g., listlessness, drowsiness, and headaches), which may rarely progress to seizures and coma. The use of desmopressin is contraindicated in patients with hyponatremia or a history of hyponatremia.

References

  1. "Product Information. Pitressin (vasopressin)." Parke-Davis, Morris Plains, NJ.
  2. Robson WLM, Norgaard JP, Leung AKC "Hyponatremia in patients with nocturnal enuresis treated with DDAVP." Eur J Pediatr 155 (1996): 959-62
  3. "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals, St. Louis, MO.
  4. Williford SL "Water intoxication in patients treated with desmopressin - reply." Pharmacotherapy 16 (1996): 970
  5. "Product Information. DDAVP (desmopressin)." Rhone-Poulenc Rorer, Collegeville, PA.
  6. Tulandi T, Beique F, Kimia M "Pulmonary edema: a complication of local injection of vasopressin at laparoscopy." Fertil Steril 66 (1996): 478-80
  7. Lin TW, Kuo YS "Acute pulmonary oedema following administration of vasopressin for control of massive GI tract haemorrhage in a major burn patient." Burns 22 (1996): 73-5
  8. Robson WLM "Water intoxication in patients treated with desmopressin." Pharmacotherapy 16 (1996): 969-70
View all 8 references
Moderate

Desmopressin (applies to DDAVP) thrombotic events

Moderate Potential Hazard, Low plausibility. Applicable conditions: Thrombotic/Thromboembolic Disorder, History - Thrombotic/Thromboembolic Disorder

Rare cases of thrombotic events (thrombosis, acute cerebrovascular thrombosis, and acute myocardial infarction) have been reported following desmopressin injection in patients predisposed to thrombus formation. Although a causal relationship has not been established, therapy with desmopressin should be administered cautiously in patients with a current or past history of thrombotic or thromboembolic disorders.

References

  1. "Product Information. DDAVP (desmopressin)." Rhone-Poulenc Rorer, Collegeville, PA.
  2. Vermylen J, Peerlinck K "Fatal complication of desmopressin." Lancet 346 (1995): 447
  3. "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals, St. Louis, MO.
Moderate

Desmopressin (applies to DDAVP) vascular disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Ischemic Heart Disease, Hypertension

The use of desmopressin, primarily in parenteral administration and/or in large doses, has been infrequently associated with changes in blood pressure, causing either slight elevations or transient decreases with a compensatory increase in heart rate. Therapy with desmopressin, regardless of route of administration, should be administered cautiously in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease.

References

  1. "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals, St. Louis, MO.
  2. "Product Information. DDAVP (desmopressin)." Rhone-Poulenc Rorer, Collegeville, PA.

DDAVP (desmopressin) drug interactions

There are 121 drug interactions with DDAVP (desmopressin)

DDAVP (desmopressin) alcohol/food interactions

There are 2 alcohol/food interactions with DDAVP (desmopressin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.